Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution
Samuel D. Banister, Mark Connor
Handbook of experimental pharmacology (2018), pp. 191-226
Closed Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

New psychoactive substances: a review and updates
Abu Shafi, Alex J. Berry, Harry Sumnall, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 243
HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation
Joanna Mikulska, Gabriela Juszczyk, Monika Gawrońska‐Grzywacz, et al.
Brain Sciences (2021) Vol. 11, Iss. 10, pp. 1298-1298
Open Access | Times Cited: 241
Designer drugs: mechanism of action and adverse effects
Dino Luethi, Matthias E. Liechti
Archives of Toxicology (2020) Vol. 94, Iss. 4, pp. 1085-1133
Open Access | Times Cited: 213
Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market
Caitlyn Norman, Gillian Walker, Brian McKirdy, et al.
Drug Testing and Analysis (2020) Vol. 12, Iss. 4, pp. 538-554
Open Access | Times Cited: 80
Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists
Elise Wouters, Jolien Walraed, Samuel D. Banister, et al.
Biochemical Pharmacology (2019) Vol. 169, pp. 113623-113623
Closed Access | Times Cited: 79
Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA
Annelies Cannaert, Eric Sparkes, Edward Pike, et al.
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 24, pp. 4434-4446
Closed Access | Times Cited: 79
Pharmaco-toxicological effects of the synthetic cannabinoids 4F-ABUTINACA, SDB-005, and JWH-018 in mice. In vitro and in vivo studies
Xuwen Luo, Lixin Kuai, Xuesong Shi, et al.
European Journal of Pharmacology (2025), pp. 177586-177586
Closed Access | Times Cited: 1
Characteristics and circumstances of synthetic cannabinoid-related death
Shane Darke, Johan Duflou, Michael Farrell, et al.
Clinical Toxicology (2019) Vol. 58, Iss. 5, pp. 368-374
Closed Access | Times Cited: 75
Enantiospecific Synthesis, Chiral Separation, and Biological Activity of Four Indazole-3-Carboxamide-Type Synthetic Cannabinoid Receptor Agonists and Their Detection in Seized Drug Samples
Lysbeth H. Antonides, Annelies Cannaert, Caitlyn Norman, et al.
Frontiers in Chemistry (2019) Vol. 7
Open Access | Times Cited: 63
Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds
Elise Wouters, Jolien Walraed, Michael J. Robertson, et al.
ACS Pharmacology & Translational Science (2019) Vol. 3, Iss. 2, pp. 285-295
Open Access | Times Cited: 56
The Basic Science of Cannabinoids
Alexandra Sideris, Justas Lauzadis, Martin Kaczocha
Anesthesia & Analgesia (2023) Vol. 138, Iss. 1, pp. 42-53
Closed Access | Times Cited: 18
In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1receptors
Shivani Sachdev, Kiran Vemuri, Samuel D. Banister, et al.
British Journal of Pharmacology (2019) Vol. 176, Iss. 24, pp. 4653-4665
Open Access | Times Cited: 50
Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists
Monica Patel, Jamie J. Manning, David B. Finlay, et al.
Biochemical Pharmacology (2020) Vol. 175, pp. 113871-113871
Closed Access | Times Cited: 47
Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L‐valine or L‐tert‐leucine
Elise Wouters, Lukas Mogler, Annelies Cannaert, et al.
Drug Testing and Analysis (2019) Vol. 11, Iss. 8, pp. 1183-1191
Open Access | Times Cited: 43
Different receptor mechanisms underlying phytocannabinoid‐ versus synthetic cannabinoid‐induced tetrad effects: Opposite roles of CB 1 /CB 2 versus GPR55 receptors
Xiao‐Fei Wang, Ewa Galaj, Guo‐Hua Bi, et al.
British Journal of Pharmacology (2019) Vol. 177, Iss. 8, pp. 1865-1880
Open Access | Times Cited: 43
Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services
Pieter E. Oomen, Dominique Schori, Karsten Tögel-Lins, et al.
International Journal of Drug Policy (2021) Vol. 100, pp. 103493-103493
Closed Access | Times Cited: 40
A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations
Caitlyn Norman, Sebastian Halter, Belal Haschimi, et al.
Drug Testing and Analysis (2021) Vol. 13, Iss. 4, pp. 841-852
Open Access | Times Cited: 35
A global review of prison drug smuggling routes and trends in the usage of drugs in prisons
Caitlyn Norman
Wiley Interdisciplinary Reviews Forensic Science (2022) Vol. 5, Iss. 2
Open Access | Times Cited: 27
Changing trends in novel benzodiazepine use within Scottish prisons: detection, quantitation, prevalence, and modes of use
Victoria Marland, Robert L. Reid, Andrew M. Brandon, et al.
Drug Testing and Analysis (2023) Vol. 16, Iss. 5, pp. 457-472
Open Access | Times Cited: 16
Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids
Michael B. Gatch, Michael J. Forster
NeuroToxicology (2018) Vol. 70, pp. 72-79
Open Access | Times Cited: 43
Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography–tandem mass spectrometry – A New Zealand perspective of use in 2018
Rui Shen Ong, Diana Kappatos, Sarah G.G. Russell, et al.
Drug Testing and Analysis (2019) Vol. 12, Iss. 2, pp. 195-214
Closed Access | Times Cited: 41
Biased agonism at the cannabinoid receptors – Evidence from synthetic cannabinoid receptor agonists
Monica Patel, David B. Finlay, Michelle Glass
Cellular Signalling (2020) Vol. 78, pp. 109865-109865
Closed Access | Times Cited: 34
Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor
Ayat Zagzoog, Asher L. Brandt, Tallan Black, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 29
Synthetic Cannabinoids and Cathinones Cardiotoxicity: Facts and Perspectives
Davide Radaelli, Alessandro Manfredi, Martina Zanon, et al.
Current Neuropharmacology (2021) Vol. 19, Iss. 11, pp. 2038-2048
Open Access | Times Cited: 27
Cannabis as a Source of Approved Drugs: A New Look at an Old Problem
Adi Gabarin, Ludmila Yarmolinsky, Arie Budovsky, et al.
Molecules (2023) Vol. 28, Iss. 23, pp. 7686-7686
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top